TIMP3 Is Reduced in Atherosclerotic Plaques From Subjects With Type 2 Diabetes and Increased by SirT1
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: Atherosclerosis is accelerated in subjects with type 2 diabetes by unknown mechanisms. We identified tissue inhibitor of metalloproteinase 3 (TIMP3), the endogenous inhibitor of A disintegrin and metalloprotease domain 17 (ADAM17) and other matrix metalloproteinases (MMPs), as a gene modifier for insulin resistance and vascular inflammation in mice. We tested its association with atherosclerosis in subjects with type 2 diabetes and identified Sirtuin 1 (SirT1) as a major regulator of TIMP3 expression. RESEARCH DESIGN AND METHODS: We investigated ADAM10, ADAM17, MMP9, TIMP1, TIMP2, TIMP3, and TIMP4 expression levels in human carotid atherosclerotic plaques (n = 60) from subjects with and without diabetes. Human vascular smooth muscle cells exposed to several metabolic stimuli were used to identify regulators of TIMP3 expression. SirT1 small interference RNA, cDNA, and TIMP3 promoter gene reporter were used to study SirT1-dependent regulation of TIMP3. RESULTS: Here, we show that in human carotid atherosclerotic plaques, TIMP3 was significantly reduced in subjects with type 2 diabetes, leading to ADAM17 and MMP9 overactivity. Reduced expression of TIMP3 was associated in vivo with SirT1 levels. In smooth muscle cells, inhibition of SirT1 activity and levels reduced TIMP3 expression, whereas SirT1 overexpression increased TIMP3 promoter activity. CONCLUSIONS: In atherosclerotic plaques from subjects with type 2 diabetes, the deregulation of ADAM17 and MMP9 activities is related to inadequate expression of TIMP3 via SirT1. Studies in vascular cells confirmed the role of SirT1 in tuning TIMP3 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
“In atherosclerotic plaques from subjects with T2DM, the deregulation of ADAM17 and MMP-9 activities is related to the inadequate expression of TIMP-3 via SirT1 [97].”
BackgroundEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Metalloproteinases and their natural inhibitors in inflammation and immunity
Khokha, R., Murthy, A., & Weiss, A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3499 · Cited by 552
Raitoharju, E., Lyytikäinen, L.-P., Levula, M., Oksala, N., Mennander, A., Tarkka, M., Klopp, N., Illig, T., Kähönen, M., Karhunen, P. J., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.020 · Cited by 448
SIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection
D'Onofrio, N., Servillo, L., & Balestrieri, M. L. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7178 · Cited by 388
Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes
Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., & Vlassara, H. (2011) · Diabetes Care · doi:10.2337/dc11-0091 · Cited by 320
“Given that downregulation of AGER1 (7–9) and SIRT1 is linked to high OS conditions (4,5), the current findings also indicate that normal SIRT1 function may depend on the ability of intact AGER1 to control AGEs and OS.”
Backgroundde Kreutzenberg, S. V., Ceolotto, G., Papparella, I., Bortoluzzi, A., Semplicini, A., Man, C. D., Cobelli, C., Fadini, G. P., & Avogaro, A. (2010) · Diabetes · doi:10.2337/db09-1187 · Cited by 301
Daniele, G., Guardado Mendoza, R., Winnier, D., Fiorentino, T. V., Pengou, Z., Cornell, J., Andreozzi, F., Jenkinson, C., Cersosimo, E., Federici, M., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-013-0543-1 · Cited by 243
Self-citationLoss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay
Fiorentino, L., Cavalera, M., Menini, S., Marchetti, V., Mavilio, M., Fabrizi, M., Conserva, F., Casagrande, V., Menghini, R., Pontrelli, P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201475 · Cited by 98
“This unexplored effect of TIMP3 on FoxO1 function in the kidney is dependent on a hyperglycaemic environment which contributes to reduce TIMP3 expression possibly through epigenetic regulation of its promoter (Cardellini et al, 2009; Federici et al, 2002).”
Self-citationThe Sirtuin System: The Holy Grail of Resveratrol?
S. Mohar, D. (2012) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000216 · Cited by 67
Jiang, J. X., Chen, X., Fukada, H., Serizawa, N., Devaraj, S., & Török, N. J. (2013) · Hepatology · doi:10.1002/hep.26491 · Cited by 49
Metadata
- Authors
- Cardellini, M., Menghini, R., Martelli, E., Casagrande, V., Marino, A., Rizza, S., Porzio, O., Mauriello, A., Solini, A., Ippoliti, A., Lauro, R., Folli, F., & Federici, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-07-06
- Volume
- 58
- Issue
- 10
- Pages
- 2396-2401
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2126730446
- Cited by
- 142
- References
- 0
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.